According to CMS, MA plans will see an average payment increase of 3.32% from 2023 to 2024, worth approximately $13.8 billion in increases for next year.

“Medications shouldn’t cost an arm and a leg, metaphorically or literally,” says Ohio Attorney General Dave Yost “Insulin is just a symptom of the problem; PBMs are the disease.”

A whopping 94% of health leaders in the survey said they plan to invest in software this year, partly to fend off clinician burnout and a looming recession.

The move comes after the company reported revenues of $26.3 billion in 2022 and and a net income of more than $6.55 billion.

Federal investigations that began in 2019 into Amazon’s potential abuse of power and consumer privacy violations may soon come to fruition with lawsuits to block the company's monopoly status, Politico reported. 

Cathie Biga, vice president of the American College of Cardiology, spoke to Cardiovascular Business at ACC.23 about challenges in the world of cardiology reimbursements. "As that healthcare dollar goes up, it is not going to the physicians," she said.

The aim of the biotech company is to “transform healthcare by providing comprehensive information on patient predisposition to disease, disease prevention and personalized intervention and treatments."

The state of California and Civica Rx have penned a 10-year deal to deliver insulin at a reduced rate. The medicines will be available in vials and prefilled pens under the CalRx label.